Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice
- PMID: 19398461
- DOI: 10.1093/jac/dkp132
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice
Abstract
Objectives: To assess the inter-individual and intra-individual plasma concentration variabilities of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) in routine clinical practice and to investigate their relationships with virological failure.
Methods: We retrospectively enrolled HIV-infected patients undergoing therapeutic drug monitoring (TDM) of NNRTIs and PIs during routine outpatient visits. Plasma drug concentrations were measured by HPLC-UV and were considered therapeutic if above the proposed minimum efficacy trough concentration. Inter-individual and intra-individual variabilities were evaluated through the coefficient of variation (CV).
Results: A total of 457 PI and 172 NNRTI plasma concentrations were measured from 363 patients (HIV-RNA <50 copies/mL in 70.8%, median CD4 count 434 cells/mm(3)). NNRTIs showed less inter-individual (CV(inter) 54.8% versus 84.3%) and intra-individual (CV(intra) 19.0% versus 38.1%) pharmacokinetic variabilities than PIs. Intra-individual variability was constantly lower than inter-individual variability for each drug. Subtherapeutic drug concentrations were observed in 106 samples (16.9%). Older age (P = 0.020) and higher viral load (P = 0.013) were associated with subtherapeutic levels. Patients with therapeutic levels had a viral load of <50 copies/mL more frequently than those with subtherapeutic levels (74.8% versus 63.2%, P = 0.020). The estimated proportion with virological failure at 24 weeks was 0.21 in patients with suboptimal baseline drug levels and 0.08 in those with optimal levels (P < 0.001). In the multivariate analysis, therapeutic drug levels showed an independent negative association with virological failure (P = 0.004).
Conclusions: A wide inter-individual and limited intra-individual pharmacokinetic variabilities, together with the demonstration of a concentration-response relationship, suggest that TDM is a useful tool for the clinical management of patients treated with NNRTIs or PIs.
Similar articles
-
Clinical benefit of interventions driven by therapeutic drug monitoring.HIV Med. 2005 Sep;6(5):360-5. doi: 10.1111/j.1468-1293.2005.00321.x. HIV Med. 2005. PMID: 16156885
-
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.HIV Med. 2010 May;11(5):326-33. doi: 10.1111/j.1468-1293.2009.00785.x. Epub 2010 Dec 9. HIV Med. 2010. PMID: 20070407
-
Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.Clin Ther. 2007 Jul;29(7):1448-55. doi: 10.1016/j.clinthera.2007.07.025. Clin Ther. 2007. PMID: 17825696
-
Protease inhibitor plasma concentrations in HIV antiretroviral therapy.Dan Med Bull. 2008 Nov;55(4):165-85. Dan Med Bull. 2008. PMID: 19232158 Review.
-
Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.Antivir Ther. 2005;10(1):29-40. Antivir Ther. 2005. PMID: 15751761 Review.
Cited by
-
Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.BMC Pharmacol Toxicol. 2018 Oct 23;19(1):66. doi: 10.1186/s40360-018-0258-6. BMC Pharmacol Toxicol. 2018. PMID: 30352627 Free PMC article. Clinical Trial.
-
Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.J Clin Pharmacol. 2011 Nov;51(11):1539-48. doi: 10.1177/0091270010385118. Epub 2011 Jan 5. J Clin Pharmacol. 2011. PMID: 21209245 Free PMC article. Clinical Trial.
-
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.HIV Clin Trials. 2011 Jul-Aug;12(4):201-14. doi: 10.1310/hct1204-201. HIV Clin Trials. 2011. PMID: 22044856 Free PMC article. Clinical Trial.
-
Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome.Intern Med. 2016;55(20):3059-3063. doi: 10.2169/internalmedicine.55.6777. Epub 2016 Oct 15. Intern Med. 2016. PMID: 27746450 Free PMC article.
-
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.Infection. 2014 Aug;42(4):775-8. doi: 10.1007/s15010-014-0599-z. Epub 2014 Feb 15. Infection. 2014. PMID: 24531907
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous